Cardiology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "PCSK9 inhibitors"

New detailed data from the phase 3 YUKAWA-2 study evaluating Evolocumab ( Repatha ), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and hig ...

Evolocumab ( Repatha ), a PCSK9 inhibitor, has shown to dramatically lower levels of low-density lipoprotein ( LDL), and also the risk of cardiovascular events in patients with existing heart or vascu ...